Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis

• Status: Terminated
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Nosocomial spontaneous bacterial peritonitis (SBP) is frequently caused by multi drug resistant bacteria. Standard treatment of SBP could be ineffective. The aim of the study is to compare daptomycin + meropenem vs ceftazidime in the treatment of nosocomial SBP.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Padova
• Treatments: Ceftazidime; Daptomycin; Meropenem; Thienamycins

Criteria

Inclusion Criteria:

• Patients with liver cirrhosis and ascites

• Meets all criteria for nosocomial SBP as outlined below

• Ascitic fluid polymorphonuclear cells count >250/mm3

• Onset of signs and symptoms of infection after 72 hours of hospitalization

Exclusion Criteria:

• Hepatocellular carcinoma beyond the Milan criteria

• Abdominal surgery within 4 weeks

• Evidence of secondary peritonitis, pancreatitis or peritoneal carcinomatosis

• Significant heart or respiratory failure

• Allergy to ceftazidime, meropenem or daptomycin